Investigation Report on China’s Paclitaxel Market 2021-2025 – ResearchAndMarkets.com


DUBLIN–()–The “Investigation Report on China’s Paclitaxel Market 2021-2025” report has been added to ResearchAndMarkets.com’s offering.

The analyst analyzes that the Paclitaxel sales in China will increase steadily with the increase in breast cancer patients from 2021 to 2025. In 2020, the number of new cases of breast cancer worldwide reached 2.26 million, and breast cancer is the most commonly diagnosed cancer, overtaking lung cancer.

Therefore, the sales and sales volume of Paclitaxel for the treatment of breast cancer will increase accordingly with the increase in the number of patients diagnosed. Furthermore, Paclitaxel will be included in the National Drug Price Negotiation in 2021, and then its sales will keep a continuous rise. In addition, the effective alleviation of the Covid-19 epidemic will lead to a recovery growth in the sales of Paclitaxel.

Paclitaxel is a chemotherapeutic tumor drug used to treat metastatic breast cancer after failure of combination chemotherapy or relapse within 6 months after adjuvant chemotherapy. Its product, developed by Abolis, was approved by the FDA in 2005 and was approved in China in 2008. By 2020, there are 34 manufacturers in the Chinese Paclitaxel market, with Nanjing Luye Pharmaceutical Co., Ltd. accounting for the most market share in the Chinese Paclitaxel market.

According to the analyst analysis, the sales of Paclitaxel in the Chinese market increased year by year from 2016 to 2019. Among them, the annual growth rate of 40.86% was the highest in 2019, from CNY2.168 billion in 2018 to CNY3.053 billion in 2019. In 2020, the hospital’s overall diagnosis and treatment services were impacted by the Covid-19 epidemic, and Paclitaxel was included in the second batch of national organization drug procurement due to more than 3 manufacturers.

With the sharp price reduction in centralized procurement, Paclitaxel sales have declined with a growth rate of -18.64%. The CAGR of Paclitaxel sales in the Chinese market from 2016 to 2020 was 7.16%.

Topics Covered:

  • The impact of COVID-19 on China’s Paclitaxel market
  • Sales value of China’s Paclitaxel 2016-2020
  • Competitive landscape of China’s Paclitaxel market
  • Prices of Paclitaxel in China
  • Prices of Paclitaxel in China by regions and manufacturers
  • Analysis of factors affecting the development of China’s Paclitaxel market
  • Prospect of China’s Paclitaxel market from 2021 to 2025

Key Topics Covered:

1 Relevant Concepts of Paclitaxel

1.1 Indications for Paclitaxel

1.2 Development of Paclitaxel in China

1.3 Governmental Approval of Paclitaxel in China

1.4 The Impact of COVID-19 on Paclitaxel sales in China

2 Sales of Paclitaxel in China, 2016-2020

2.1 Sales Value of Paclitaxel

2.1.1 Overall Sales Value

2.1.2 Sales Value by Regions

2.2 Sales Volume of Paclitaxel

2.2.1 Overall Sales Volume

2.2.2 Sales Volume by Regions

2.3 Sales of Paclitaxel by Dosage Form in China, 2016-2020

2.3.1 Liposome injection

2.3.2 Injection (nanoparticle albumin-bound)

2.3.3 Injection

2.3.4 Analysis of Other Dosage Forms

3 Analysis of Major Paclitaxel Manufacturers in China, 2016-2020

3.1 Analysis of Market Share of Major Paclitaxel Manufacturers

3.1.1 Investigation on Market Share by Sales Value

3.1.2 Investigation on Market Share by Sales volume

3.2 Nanjing Luye Pharmaceutical Co., Ltd.

3.2.1 Enterprise Profile

3.2.2 Sales of LIPOSOME (Nanjing Luye Pharmaceutical Co., Ltd.’s Paclitaxel) in China

3.3 CSPC Ouyi Pharmaceutical Group Co., Ltd.

3.3.1 Enterprise Profile

3.3.2 Sales of Keaili (CSPC Ouyi Pharmaceutical Group Co., Ltd.’s Paclitaxel) in China

3.4 Jiangsu Hengrui Pharmaceutical Co., Ltd.

3.4.1 Enterprise Profile

3.4.2 Sales of Aiyue (Jiangsu Hengrui Pharmaceutical Co., Ltd.’s Paclitaxel) in China

3.5 Hospira Australia Pty Ltd

3.5.1 Enterprise Profile

3.5.2 Sales of Paclitaxel (Hospira Australia Pty Ltd’s Paclitaxel) in China

3.6 Beistol-Myers Squibb S.r.l.

3.6.1 Enterprise Profile

3.6.2 Sales of TAXOL (Beistol-Myers Squibb S.r.l.’s Paclitaxel) in China

4 Prices of Paclitaxel for Different Manufacturers in China, 2020-2021

4.1 Nanjing Luye Pharmaceutical Co., Ltd. (LIPOSOME)

4.2 CSPC Ouyi Pharmaceutical Group Co., Ltd. (Keaili)

4.3 Jiangsu Hengrui Pharmaceutical Co., Ltd. (Aiyue)

4.4 Hospira Australia Pty Ltd (ANZATAX)

4.5 Beistol-Myers Squibb S.r.l.(TAXOL)

5 Prospect of Chinese Paclitaxel Market, 2021-2025

5.1 Influential Factors of Chinese Paclitaxel Market Development

5.1.1 The Impact of COVID-19 on Chinese Paclitaxel Market

5.1.2 Market Drivers and Opportunities

5.1.3 Market Threats and Challenges

5.2 Forecast on Market Size

5.3 Forecast on Market Trend

For more information about this report visit https://www.researchandmarkets.com/r/jhmk1u



Source link

The content is by Business Wire. Headlines of Today Media is not responsible for the content provided or any links related to this content. Headlines of Today Media is not responsible for the correctness, topicality or the quality of the content.

Comments are closed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy